Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilumira
- Development stage
- Preclinical
- Lead developer
- SHINE Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ilumira is the brand name for **non-carrier added lutetium-177 chloride**, a radioactive isotope used as a radiopharmaceutical for targeted cancer therapy. It delivers beta radiation directly to tumor cells, particularly in the treatment of neuroendocrine tumors and prostate cancer, among others. This targeted radiotherapy approach helps minimize damage to surrounding healthy tissues while maximizing tumor cell kill. Ilumira is produced using advanced nuclear technology to yield a highly pure, non-carrier added form of lutetium-177, improving predictability and efficacy in radiopharmaceutical treatments.
- Brand names
- ilumira
Beyond the preview
Go deeper on ilumira.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilumira.